TORONTO, July 11 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (“Spectral”), today announced the commercial placement of their proprietary sepsis assay system (“EAA(TM)”) in two of Italy’s largest hospitals though Estor S.p.A. (“Estor”), a major distributor of medical products in Italy. These systems measure circulating Endotoxin in patients and give accurate results in less than 30 minutes, enabling rapid initiation of appropriate treatment, and monitoring of its effectiveness.
Estor was established on May 1, 1999 as a spin-off of the Hospital Supply Division of Aventis (ex-Hoechst). The sales team has been operating in the fields of Dialysis since 1980, Interventional Cardiology since 1990 and ICU from 1999, distributing unique and innovative products such as Toray PMMA based dialysers, and the Toray Endotoxin absorption cartridge (“Toraymyxin”).
“We are very pleased to see this uptake of the EAA(TM). Estor is an experienced and knowledgeable distributor of products, using a ‘theranostics approach’, aimed at reducing the impact of sepsis,” stated Dr. Paul Walker, President & CEO of Spectral. “This early adoption of equipment and tests for the EAA(TM) in Italy should lead to increased revenue in the latter part of our current fiscal year.” added Dr. Walker.
“Estor has been engaged in the promotion of Toraymyxin, the cartridge for extracorporeal removal of Endotoxin, for more than 4 years treating more than 1000 patients in Italy. We now have the appropriate diagnostic tool for detecting Endotoxemia and properly selecting patients for the use of Toraymyxin. We strongly believe that the association between EAA(TM) and Toraymyxin could represent a revolution in the management of septic shock,” commented Dr. Federico D’Avanzo, President of Estor.
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral’s rapid West Nile Virus assay and its FDA approved rapid diagnostic for sepsis, the EAA(TM), as well as a range of other biological reagents. Spectral’s common shares are listed on The Toronto Stock Exchange: SDI.
Information in this news release that is not current or historically factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, the future outlook of Spectral and anticipated events or results are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Spectral Diagnostics Inc.
CONTACT: Spectral Diagnostics Inc., Dr. Paul Walker, Chief ExecutiveOfficer, (416) 626-3233
